Targeting KRAS in Lung Cancer: The Past, Present, and Future | IASLC

Source : https://www.iaslc.org/iaslc-news/ilcn/targeting-kras-lung-cancer-past-present-and-future

Although RAS mutations constitute some of the most common genetic alterations in patients with adenocarcinomas, efforts to target the RAS oncoprotein have not proven fruitful, not only in NSCLC but across all cancers. In fact, researchers have been searching for an effective RAS inhibitor for more than 3 decades, leading many to believe that RAS is "undruggable."